Education
About Us
Working with TipRanks
Follow Us
Immucell Corp. (ICCC)
NASDAQ:ICCC
ICCC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.38 - $7.60
Previous CloseN/A
Volume9.49K
Average Volume (3M)8.22K
Market Cap
$54.82M
Enterprise Value$71.12M
Total Cash (Recent Filing)$6.00M
Total Debt (Recent Filing)$14.27M
Price to Earnings (P/E)32.1
Beta-0.18
Next Earnings
Nov 17, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.06
Shares Outstanding9,045,851
10 Day Avg. Volume10,033
30 Day Avg. Volume8,216
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.30
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit0.02
Enterprise Value/Ebitda13.27
Forecast
1Y Price Target
$6.00Price Target Upside-0.50% Downside
Rating ConsensusHold
Number of Analyst Covering0
Immucell News
ICCC FAQ
What was Immucell Corp.’s price range in the past 12 months?
Immucell Corp. lowest stock price was $3.38 and its highest was $7.60 in the past 12 months.
What is Immucell Corp.’s market cap?
Immucell Corp.’s market cap is $54.82M.
When is Immucell Corp.’s upcoming earnings report date?
Immucell Corp.’s upcoming earnings report date is Nov 17, 2025 which is in 51 days.
How were Immucell Corp.’s earnings last quarter?
Immucell Corp. released its earnings results on Aug 14, 2025. The company reported $0.056 earnings per share for the quarter, beating the consensus estimate of N/A by $0.056.
Is Immucell Corp. overvalued?
According to Wall Street analysts Immucell Corp.’s price is currently Overvalued.
Does Immucell Corp. pay dividends?
Immucell Corp. does not currently pay dividends.
What is Immucell Corp.’s EPS estimate?
Immucell Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Immucell Corp. have?
Immucell Corp. has 9,045,851 shares outstanding.
What happened to Immucell Corp.’s price movement after its last earnings report?
Immucell Corp. reported an EPS of $0.056 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -9.226%.
Which hedge fund is a major shareholder of Immucell Corp.?
Currently, no hedge funds are holding shares in ICCC
Immucell Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$6.00 (-0.50% Downside)
$6.00 (-0.50% Downside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
66.98%
12-Months-Change
Fundamentals
Return on Equity
6.61%
Trailing 12-Months
Asset Growth
11.62%
Trailing 12-Months
Company Description
Immucell Corp.
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
ICCC Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
ImmuCell showed strong financial performance with significant sales growth and gross margin improvement, alongside a successful debt refinancing. However, challenges remain with potential sales softening, FDA approval delays for Re-Tain, and the need to regain customer trust after supply issues.View all ICCC earnings summariesTechnical Analysis
Medicinova
―
Adicet Bio
―
Werewolf Therapeutics
―
Telomir Pharmaceuticals, Inc.
―
Artiva Biotherapeutics, Inc.
―
Ownership Overview
1.58% Insiders
4.50% Mutual Funds
3.62% Other Institutional Investors
87.05% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---